



# International Journal of Pharma Insight Studies

## Plant-Based Drug Discovery: From Ethnomedicine to Modern Therapeutics— Translational Strategies, Phytochemical Innovation, and Clinical Integration

Dr. Li Wenhao <sup>1\*</sup>, Dr. Wang Meilin <sup>2</sup>

<sup>1</sup> Professor, Department of Natural Products Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

<sup>2</sup> Professor, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China

\* Corresponding Author: **Dr. Li Wenhao**

---

### Article Info

**ISSN (online):** 3107-393X

**Volume:** 01

**Issue:** 01

**January – February 2024**

**Received:** 01-11-2023

**Accepted:** 03-12-2023

**Published:** 05-01-2024

**Page No:** 01-07

### Abstract

Plant-based drug discovery represents a critical intersection between traditional ethnomedicine and contemporary pharmaceutical development, offering a rich repository of structurally diverse bioactive compounds with validated therapeutic potential. This review examines the translational continuum from ethnobotanical knowledge to clinically approved therapeutics, emphasizing pharmacologically relevant strategies that have successfully bridged indigenous healing practices with evidence-based medicine. Ethnomedicine-guided bioprospecting has yielded numerous lead compounds targeting complex diseases, including cancer, infectious diseases, cardiovascular disorders, and neurodegenerative conditions. The phytochemical diversity inherent in medicinal plants provides scaffolds for novel drug candidates, with alkaloids, terpenoids, polyphenols, and glycosides demonstrating specific molecular interactions with validated therapeutic targets. Modern drug development approaches integrate advanced screening platforms, omics technologies, and computational modeling to accelerate the identification and optimization of plant-derived bioactives. Despite significant successes, translational barriers persist, including standardization challenges, bioavailability limitations, and regulatory complexities that impede the progression from preclinical validation to clinical implementation. This review synthesizes current knowledge on plant-based drug discovery pipelines, mechanistic pharmacology of key phytochemicals, and strategies for overcoming translational obstacles. By examining both established plant-derived therapeutics and emerging candidates in clinical development, we provide a comprehensive framework for leveraging botanical resources in modern drug discovery. Future directions emphasize the integration of artificial intelligence, systems pharmacology, and precision medicine approaches to unlock the full therapeutic potential of the plant kingdom.

**DOI:** <https://doi.org/10.54660/IJPIS.2024.1.1.01-07>

**Keywords:** Ethnomedicine, Phytochemistry, Drug Discovery, Natural Products, Translational Pharmacology, Bioactive Compounds

---

### 1. Introduction

The exploitation of plant-derived compounds for therapeutic purposes has profoundly shaped the evolution of modern pharmacotherapy, with approximately 25-50% of currently marketed drugs either directly derived from or inspired by natural products <sup>[1, 2]</sup>. The transition from empirical ethnomedicinal practices to mechanism-based drug development represents a paradigm shift in how botanical resources are evaluated and translated into clinically efficacious therapeutics. Medicinal plants have served as primary healthcare resources across diverse cultures for millennia, accumulating empirical knowledge that provides validated starting points for systematic pharmacological investigation <sup>[3, 4]</sup>. This traditional knowledge, when subjected to rigorous scientific scrutiny, has yielded transformative therapeutics including morphine, quinine, digoxin, paclitaxel, and

artemisinin [5, 6]. The molecular complexity inherent in plant secondary metabolites offers distinct advantages over synthetic compound libraries, including enhanced structural diversity, biological relevance through evolutionary optimization, and the presence of privileged scaffolds that exhibit favorable pharmacological properties [7, 8]. Plants synthesize these compounds as adaptive responses to environmental pressures, resulting in molecules pre-optimized for biological activity through millions of years of natural selection [9]. Contemporary drug discovery increasingly recognizes ethnomedicine not merely as historical curiosity but as a rational strategy for identifying pharmacologically relevant lead compounds with established safety profiles and documented efficacy in human populations [10, 11].

This review examines the translational pathway from ethnomedicinal validation through phytochemical characterization to clinical development, emphasizing mechanistic pharmacology, molecular target identification, and strategies for overcoming the challenges that have historically limited the pharmaceutical exploitation of plant-derived therapeutics.

## 2. Ethnomedicine as a Foundation for Drug Discovery

Ethnomedicine represents a systematically curated biological library, wherein traditional healing practices have subjected plant species to multi-generational empirical testing in human populations [12, 13]. This extensive observational screening provides crucial preliminary evidence of therapeutic efficacy and safety, significantly de-risking the drug development process by prioritizing species with documented bioactivity [14]. Ethnopharmacological investigations have demonstrated that plants selected through traditional use show substantially higher hit rates in pharmacological assays compared to randomly selected species, validating the predictive value of indigenous knowledge [15, 16].

The integration of ethnobotanical data into modern drug discovery pipelines employs

systematic methodologies including ethnobotanical surveys, pharmacological validation studies, and reverse pharmacology approaches that work backward from clinical observations to molecular mechanisms [17, 18]. Quantitative ethnobotany utilizes informant consensus, use-value calculations, and fidelity levels to prioritize species for pharmacological investigation, ensuring that research resources focus on plants with the strongest ethnomedicinal validation [19, 20]. Case studies exemplifying successful ethnomedicine-guided discovery include the development of artemisinin from *Artemisia annua*, validated through traditional Chinese medicine for treating fevers, and the identification of vincristine and vinblastine from *Catharanthus roseus*, informed by Caribbean traditional medicine [21, 22].

Indigenous knowledge systems employ sophisticated classification schemes and preparation methodologies that influence phytochemical composition and bioavailability, information that proves critical for developing optimal extraction and formulation strategies [23, 24]. The documentation and preservation of this knowledge, conducted ethically with appropriate benefit-sharing arrangements, remains essential for sustained bioprospecting efforts and represents a moral imperative given the erosion of traditional practices and biodiversity loss [25].

## 3. Phytochemical Diversity and Bioactive Compounds

Plant secondary metabolites encompass extraordinary structural diversity, with over 200,000 characterized compounds representing multiple chemical classes including alkaloids, terpenoids, phenolic compounds, glycosides, and polyketides [26, 27]. This molecular diversity arises from complex biosynthetic pathways that generate structurally sophisticated compounds exhibiting diverse pharmacophores capable of selective interactions with biological macromolecules [28]. Table 1 summarizes representative medicinal plants, their principal bioactive constituents, and documented therapeutic applications.

**Table 1:** Representative Medicinal Plants and Key Bioactive Compounds

Plant Species	Bioactive Compound(s)	Chemical Class	Traditional Use	Validated Activity
<i>Papaver somniferum</i>	Morphine, Codeine	Alkaloids	Pain, Sedation	Analgesic, Antitussive
<i>Digitalis purpurea</i>	Digoxin, Digitoxin	Cardiac Glycosides	Heart Conditions	Cardiac Glycoside
<i>Cinchona officinalis</i>	Quinine	Alkaloid	Fever, Malaria	Antimalarial
<i>Taxus brevifolia</i>	Paclitaxel	Diterpene	Various	Antineoplastic
<i>Artemisia annua</i>	Artemisinin	Sesquiterpene Lactone	Fever	Antimalarial
<i>Catharanthus roseus</i>	Vincristine, Vinblastine	Vinca Alkaloids	Diabetes	Antineoplastic
<i>Salvia miltiorrhiza</i>	Tanshinones	Diterpene Quinones	Cardiovascular	Cardioprotective
<i>Curcuma longa</i>	Curcumin	Polyphenol	Inflammation	Anti-inflammatory

Alkaloids represent nitrogen-containing heterocyclic compounds that frequently exhibit potent pharmacological activity through interactions with neurotransmitter systems, enzyme active sites, and receptor proteins [29]. Morphine exemplifies alkaloid pharmacology, binding stereospecifically to  $\mu$ -opioid receptors to produce analgesia, while berberine demonstrates multi-target activity including AMPK activation and antimicrobial properties [30, 31]. Terpenoids, constructed from isoprene units, constitute the largest class of natural products and include paclitaxel, which stabilizes microtubules to arrest cell division, and artemisinin, which generates reactive oxygen species through iron-catalyzed cleavage [32, 33].

Phenolic compounds encompass diverse structures from simple phenolic acids to complex polyphenols like flavonoids and tannins, exhibiting antioxidant, anti-inflammatory, and enzyme-modulatory activities [34]. Curcumin demonstrates pleiotropic effects through modulation of NF- $\kappa$ B signaling, cyclooxygenase inhibition, and antioxidant activity, though clinical translation has been limited by poor bioavailability [35]. Cardiac glycosides such as digoxin inhibit Na<sup>+</sup>/K<sup>+</sup>-ATPase, increasing intracellular calcium and cardiac contractility, representing a therapeutic class derived entirely from plant sources [36].

The structural complexity of plant-derived compounds often incorporates multiple stereogenic centers and intricate

scaffolds that prove synthetically challenging, making botanical sources essential for compound supply and serving as templates for semi-synthetic modifications that enhance

pharmacological properties [37]. Figure 1 illustrates the discovery workflow from ethnomedicinal knowledge through compound isolation to clinical development.



Fig 1: Translational Workflow from Ethnomedicine to Clinical Development

#### 4. Modern Approaches in Plant-Based Drug Development

Contemporary plant-based drug discovery integrates advanced technologies that dramatically accelerate the identification, characterization, and optimization of bioactive phytochemicals [38]. High-throughput screening platforms enable rapid evaluation of plant extracts and isolated compounds against validated molecular targets, while bioactivity-guided fractionation employs iterative extraction, chromatographic separation, and biological assaying to track active principles through complex mixtures [39, 40].

Metabolomics approaches utilizing liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy provide comprehensive phytochemical profiling, facilitating dereplication strategies that prevent redundant investigation of known compounds and enabling

discovery of novel structures [41, 42]. Genomics and transcriptomics elucidate biosynthetic pathways responsible for bioactive compound production, enabling metabolic engineering approaches to enhance yields or generate novel analogs through pathway manipulation [43].

Target-based screening employs recombinant proteins, cell-based assays, and phenotypic screening to identify compounds modulating specific disease-relevant targets including enzymes, receptors, ion channels, and protein-protein interactions. Structure-activity relationship (SAR) studies systematically evaluate how chemical modifications influence biological activity, guiding rational drug design and optimization of pharmacokinetic and pharmacodynamic properties. Table 2 details mechanisms of action for representative plant-derived drug candidates.

Table 2: Mechanisms of Action of Plant-Derived Drug Candidates

Compound	Source Plant	Molecular Target(s)	Mechanism of Action	Therapeutic Application
Paclitaxel	<i>Taxus brevifolia</i>	$\beta$ -Tubulin	Microtubule stabilization	Cancer chemotherapy
Artemisinin	<i>Artemisia annua</i>	Heme, PfATP6	ROS generation, $\text{Ca}^{2+}$ -ATPase inhibition	Malaria treatment
Berberine	<i>Berberis</i> spp.	AMPK, QseC	Metabolic regulation, quorum sensing	Diabetes, Infection
Resveratrol	<i>Vitis vinifera</i>	SIRT1, COX	Sirtuin activation, COX inhibition	Cardioprotection
Galantamine	<i>Galanthus</i> spp.	Acetylcholinesterase	Enzyme inhibition	Alzheimer's disease
Silymarin	<i>Silybum marianum</i>	NF- $\kappa$ B, Antioxidant	Transcription modulation, ROS scavenging	Hepatoprotection
Capsaicin	<i>Capsicum</i> spp.	TRPV1	Ion channel activation/desensitization	Pain management
Forskolin	<i>Coleus forskohlii</i>	Adenylyl cyclase	Enzyme activation, cAMP elevation	Glaucoma, Asthma

Computational approaches including molecular docking, pharmacophore modeling, and QSAR (quantitative structure-activity relationship) analysis predict compound-target interactions and optimize lead structures in silico prior to synthesis and testing. Network pharmacology and systems biology approaches recognize that many plant-derived

compounds exhibit multi-target activity, acting on complex disease networks rather than single molecular targets, an approach particularly relevant for chronic diseases with multifactorial etiologies. Figure 2 categorizes major phytochemical classes with representative molecular targets.




Fig 2: Major Phytochemical Classes and Molecular Targets

## 5. Therapeutic Applications

Plant-derived compounds have demonstrated clinical efficacy across diverse therapeutic areas, with particularly

significant contributions to oncology, infectious diseases, cardiovascular medicine, and neurology. Table 3 summarizes therapeutic applications organized by disease category.

Table 3: Therapeutic Applications of Plant-Derived Compounds Across Disease Areas

Therapeutic Area	Plant Source	Active Compound(s)	Clinical Application	Development Status
Oncology	<i>Taxus brevifolia</i>	Paclitaxel	Breast, ovarian, lung cancer	FDA approved
	<i>Podophyllum peltatum</i>	Etoposide	Testicular, lung cancer	FDA approved
	<i>Camptotheca acuminata</i>	Irinotecan, Topotecan	Colorectal, ovarian cancer	FDA approved
Infectious Diseases	<i>Artemisia annua</i>	Artemisinin	Malaria	WHO essential medicine
	<i>Cinchona</i> spp.	Quinine	Malaria	FDA approved
	<i>Berberis</i> spp.	Berberine	Bacterial, fungal infections	Clinical trials
Cardiovascular	<i>Digitalis</i> spp.	Digoxin	Heart failure, arrhythmias	FDA approved
	<i>Coleus forskohlii</i>	Forskolin	Hypertension, glaucoma	Phase II trials
Neurology	<i>Galanthus</i> spp.	Galantamine	Alzheimer's disease	FDA approved
	<i>Cannabis sativa</i>	Cannabinoids	Multiple sclerosis, epilepsy	FDA approved
Metabolic	<i>Salacia</i> spp.	Salacinol	Type 2 diabetes	Clinical development
	<i>Cinnamomum</i> spp.	Cinnamaldehyde	Diabetes, dyslipidemia	Preclinical/Phase I

In oncology, plant-derived compounds have revolutionized cancer chemotherapy through diverse mechanisms including microtubule disruption (vinca alkaloids, taxanes), topoisomerase inhibition (camptothecins, podophyllotoxins), and apoptosis induction. Paclitaxel exemplifies successful clinical translation, progressing from ethnobotanical observation through structure elucidation to becoming a first-line therapy for multiple malignancies, though supply challenges initially required semi-synthesis and later cell culture production.

Antimalarial agents artemisinin and quinine represent landmark achievements in plant-based infectious disease therapy, with artemisinin combination therapies now constituting WHO-recommended first-line malaria treatment [56]. The identification of artemisinin through traditional Chinese medicine screening programs and its subsequent development demonstrates the continued relevance of ethnomedicine-guided approaches even in the genomic era. Cardiovascular therapeutics derived from plants include cardiac glycosides for heart failure management and various compounds with antihypertensive, antiplatelet, and lipid-

lowering activities currently in clinical development [58]. The transition of forskolin from traditional Ayurvedic medicine to clinical investigation for glaucoma and cardiovascular indications illustrates the translational pathway for botanicals with established traditional use.

Neurodegenerative disease therapy has benefited substantially from plant-derived acetylcholinesterase inhibitors including galantamine and rivastigmine for Alzheimer's disease, while cannabinoid-based medications address spasticity, seizures, and pain in various neurological conditions. The endocannabinoid system exemplifies a therapeutic target discovered through investigation of plant-derived psychoactive compounds, leading to fundamental advances in neuropharmacology and drug development.

## 6. Challenges and Translational Barriers

Despite numerous successes, plant-based drug development faces substantial challenges that impede efficient translation from discovery to clinical implementation. Table 4 outlines key advantages, limitations, and translational obstacles.

**Table 4:** Advantages, Limitations, and Translational Challenges in Plant-Based Drug Development

Advantages	Limitations	Translational Barriers
Structural diversity and complexity	Variable phytochemical composition	Standardization and quality control
Evolutionarily optimized bioactivity	Low abundance of bioactive compounds	Sustainable sourcing and supply
Ethnomedicinal validation	Complex mixture effects	Isolation and purification costs
Multi-target therapeutic potential	Poor bioavailability (many compounds)	Regulatory pathway ambiguity
Established safety in traditional use	Herb-drug interactions	Intellectual property complexities
Novel mechanism discovery	Batch-to-batch variability	Clinical trial design challenges
Reduced development risk	Limited mechanistic understanding	Lack of pharmaceutical investment

Standardization represents a critical challenge, as phytochemical composition varies substantially based on genetic factors, environmental conditions, harvest timing, and post-harvest processing. This variability complicates quality control, dose optimization, and regulatory approval processes. Advanced analytical methodologies including metabolomic fingerprinting and chemometric analysis provide approaches for ensuring consistency, though implementation requires significant technical expertise and infrastructure.

Bioavailability limitations plague many promising phytochemicals, particularly polyphenols and hydrophilic glycosides that exhibit poor absorption, extensive first-pass metabolism, or rapid elimination. Formulation strategies including nanoparticle delivery systems, liposomal encapsulation, and prodrug approaches have shown promise for enhancing bioavailability, though these modifications add complexity and cost to development programs.

Sustainable sourcing emerges as both an ecological and pharmaceutical concern, particularly for species with slow growth rates or limited geographic distribution. The near-extinction of *Taxus brevifolia* during paclitaxel development highlights the urgent need for alternative production strategies including plant cell culture, biosynthetic pathway engineering in heterologous hosts, and total synthesis.


Regulatory pathways for plant-derived therapeutics remain complex and sometimes ambiguous, with distinctions between botanical drugs, isolated natural products,

and semi-synthetic derivatives influencing approval requirements. The FDA botanical drug pathway provides one regulatory mechanism, though few products have successfully navigated this route, and requirements for standardization, mechanism elucidation, and clinical efficacy remain stringent.

Intellectual property considerations present unique challenges for plant-based discoveries, particularly regarding traditional knowledge rights, benefit-sharing arrangements under the Nagoya Protocol, and patentability of naturally occurring substances versus isolated and purified compounds or novel derivatives. Ethical bioprospecting practices with equitable benefit distribution remain essential for sustainable drug discovery partnerships with indigenous communities and biodiversity-rich nations.

## 7. Future Perspectives

The future of plant-based drug discovery lies in integrating traditional knowledge with cutting-edge technologies to accelerate identification, optimization, and translation of botanical therapeutics. Artificial intelligence and machine learning applications promise to revolutionize compound prediction, target identification, and clinical outcome forecasting by analyzing vast datasets encompassing chemical structures, biological activities, and clinical outcomes. Figure 3 depicts the modern translational pathway incorporating advanced methodologies.

**Fig 3:** Modern Translational Pathway for Plant-Based Therapeutics

Systems pharmacology approaches recognize the multi-component, multi-target nature of plant-derived therapeutics and model complex interactions within biological networks

to predict efficacy and toxicity. This paradigm shift from single-target to network-based drug discovery aligns particularly well with plant-based medicines that often

exhibit synergistic effects through simultaneous modulation of multiple pathways.

Precision medicine frameworks will enable identification of patient populations most likely to respond to specific plant-derived therapeutics based on genetic polymorphisms affecting drug metabolism, target expression profiles, and disease subtypes. Pharmacogenomic studies of natural product metabolism and response may reveal biomarkers predicting therapeutic outcomes, enabling rational patient stratification in clinical trials.

Synthetic biology and metabolic engineering offer transformative approaches for sustainable production of complex plant-derived compounds through pathway reconstruction in microbial hosts or plant cell cultures, circumventing supply limitations and ecological concerns<sup>[85, 86]</sup>. Recent successes in engineering yeast and bacteria to produce artemisinin, opiate alkaloids, and other complex terpenoids demonstrate the feasibility of biotechnological production at commercial scale.

The integration of CRISPR-based genome editing in medicinal plants enables targeted enhancement of biosynthetic pathways, potentially increasing yields of bioactive compounds or generating novel analogs through pathway engineering. Combined with modern breeding techniques and tissue culture methodologies, these approaches may establish stable, high-yielding cultivars of medicinal species with standardized phytochemical profiles. Emerging therapeutic areas for plant-based drug discovery include immunomodulation, microbiome modulation, epigenetic regulation, and senescence targeting, domains where complex multi-target activity may prove advantageous over single-target synthetic drugs. The recognition that many chronic diseases involve dysregulated networks rather than single pathway defects positions plant-derived multi-component therapeutics as potentially superior interventions.

## 8. Conclusion

Plant-based drug discovery represents a mature yet continually evolving field that has delivered transformative therapeutics while maintaining substantial untapped potential for future innovations. The systematic integration of ethnomedicinal knowledge with contemporary pharmacological methodologies provides a rational, efficient approach for identifying novel drug candidates with validated biological activity and established safety profiles. The extraordinary structural diversity of plant secondary metabolites continues to inspire drug design, provide unique pharmacological tools, and yield clinically effective therapeutics across diverse disease categories.

Modern technological advances including high-throughput screening, metabolomics, computational modeling, and synthetic biology have dramatically accelerated the pace of plant-based drug discovery while addressing longstanding challenges related to compound supply, standardization, and mechanistic understanding. The successful translation of numerous plant-derived compounds into essential medicines validates the continued investment in botanical drug discovery and demonstrates the complementary value of traditional knowledge and cutting-edge science.

Overcoming remaining translational barriers requires sustained commitment to rigorous pharmacological characterization, innovative formulation strategies, adaptive regulatory frameworks, and ethical bioprospecting practices that ensure equitable benefit sharing with source

communities and countries. The future of plant-based therapeutics lies not in opposition to synthetic drug discovery but in synergistic integration, leveraging the strengths of natural product diversity alongside the precision of rational drug design.

As we advance into an era of precision medicine, network pharmacology, and biotechnological production, plant-derived compounds will continue to serve as both therapeutic agents and molecular probes for understanding complex biological systems. The challenge before the scientific community is to fully realize this potential through interdisciplinary collaboration, sustainable practices, and unwavering commitment to translating botanical wisdom into evidence-based therapeutics that improve human health globally.

## 9. References

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J Nat Prod.* 2020;83(3):770–803.
2. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. *Nat Rev Drug Discov.* 2021;20(3):200–16.
3. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. *Environ Health Perspect.* 2001;109(Suppl 1):69–75.
4. Heinrich M, Appendino G, Efferth T, *et al.* Best practice in research – Overcoming common challenges in phytopharmacological research. *J Ethnopharmacol.* 2020;246:112230.
5. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. *Chem Rev.* 2009;109(7):3012–43.
6. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. *Nat Med.* 2011;17(10):1217–20.
7. Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. *Nat Chem.* 2016;8(6):531–41.
8. Hübner H, Hahn CK, Zwergel C, Gmeiner P. Natural product-inspired SAR studies of privileged scaffolds in drug discovery. *Nat Prod Rep.* 2020;37(7):897–923.
9. Wink M. Modes of action of herbal medicines and plant secondary metabolites. *Medicines.* 2015;2(3):251–86.
10. Veeresham C. Natural products derived from plants as a source of drugs. *J Adv Pharm Technol Res.* 2012;3(4):200–1.
11. Cordell GA, Colvard MD. Natural products and traditional medicine: turning on a paradigm. *J Nat Prod.* 2012;75(3):514–25.
12. Wachtel-Galor S, Benzie IFF. Herbal medicine: an introduction to its history, usage, regulation, current trends, and research needs. In: Benzie IFF, Wachtel-Galor S, editors. *Herbal Medicine: Biomolecular and Clinical Aspects.* 2nd ed. Boca Raton (FL): CRC Press; 2011.
13. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. *Evid Based Complement Alternat Med.* 2005;2(4):465–73.
14. Leonti M, Casu L. Traditional medicines and globalization: current and future perspectives in ethnopharmacology. *Front Pharmacol.* 2013;4:92.

15. Saslis-Lagoudakis CH, Savolainen V, Williamson EM, *et al.* Phylogenies reveal predictive power of traditional medicine in bioprospecting. *Proc Natl Acad Sci U S A.* 2012;109(39):15835–40.
16. Weckerle CS, de Boer HJ, Puri RK, van Andel T, Bussmann RW, Leonti M. Recommended standards for conducting and reporting ethnopharmacological field studies. *J Ethnopharmacol.* 2018;210:125–32.
17. Vaidya AB, Vaidya RA. Reverse pharmacology: a paradigm for developing countries? In: Mehta B, Kadam S, editors. *Principles of Medical Biology.* Vol 13. Amsterdam: Elsevier; 2000. p. 13–29.
18. Patwardhan B, Vaidya AD. Natural products drug discovery: accelerating the clinical candidate development using reverse pharmacology approaches. *Indian J Exp Biol.* 2010;48(3):220–7.
19. Heinrich M, Ankli A, Frei B, Weimann C, Sticher O. Medicinal plants in Mexico: healers' consensus and cultural importance. *Soc Sci Med.* 1998;47(11):1859–71.
20. Trotter RT, Logan MH. Informant consensus: a new approach for identifying potentially effective medicinal plants. In: Etkin NL, editor. *Plants in Indigenous Medicine and Diet.* Bedford Hills, NY: Redgrave Publishing; 1986. p. 91–112.
21. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. *Science.* 1985;228(4703):1049–55.
22. Noble RL. The discovery of the vinca alkaloids—chemotherapeutic agents against cancer. *Biochem Cell Biol.* 1990;68(12):1344–51.
23. Rivera D, Allkin R, Obón C, Alcaraz F, Verpoorte R, Heinrich M. What is in a name? The need for accurate scientific nomenclature for plants. *J Ethnopharmacol.* 2014;152(3):393–402.
24. Booker A, Frommenwiler D, Reich E, Horsfield S, Heinrich M. Adulteration and poor quality of Ginkgo biloba supplements. *J Herb Med.* 2016;6(2):79–87.
25. Schippmann U, Leaman DJ, Cunningham AB. Impact of cultivation and gathering of medicinal plants on biodiversity: global trends and issues. In: *Biodiversity and the Ecosystem Approach in Agriculture, Forestry and Fisheries.* Rome: FAO; 2002.
26. Afendi FM, Okada T, Yamazaki M, *et al.* KNApSACk family databases: integrated metabolite–plant species databases for multifaceted plant research. *Plant Cell Physiol.* 2012;53(2):e1.
27. Wink M. Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. *Phytochemistry.* 2003;64(1):3–19.
28. Croteau R, Kutchan TM, Lewis NG. Natural products (secondary metabolites). In: Buchanan B, Grissem W, Jones R, editors. *Biochemistry and Molecular Biology of Plants.* Rockville, MD: American Society of Plant Physiologists; 2000. p. 1250–1318.
29. Kutchan TM. Alkaloid biosynthesis—the basis for metabolic engineering of medicinal plants. *Plant Cell.* 1995;7(7):1059–70.
30. Inturrisi CE. Clinical pharmacology of opioids for pain. *Clin J Pain.* 2002;18(4 Suppl):S3–13.
31. Neag MA, Mocan A, Echeverría J, *et al.* Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. *Front Pharmacol.* 2018;9:557.
32. Goodman J, Walsh V. *The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug.* Cambridge: Cambridge University Press; 2001.
33. Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. *Trends Pharmacol Sci.* 2008;29(10):520–7.
34. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. *Am J Clin Nutr.* 2005;81(1 Suppl):215S–17S.
35. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm.* 2007;4(6):807–18.
36. Hauptman PJ, Kelly RA. Digitalis. *Circulation.* 1999;99(9):1265–70.
37. Shen B. A new golden age of natural products drug discovery. *Cell.* 2015;163(6):1297–1300.
38. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. *Nat Rev Drug Discov.* 2015;14(2):111–29.
39. Marston A. Thin-layer chromatography with biological detection in phytochemistry. *J Chromatogr A.* 2011;1218(19):2676–83.
40. Wolfender JL, Nuzillard JM, van der Hooft JJJ, Renault JH, Bertrand S. Accelerating metabolite identification in natural product research: toward an ideal combination of liquid chromatography–high-resolution tandem mass spectrometry and NMR profiling, in silico databases, and chemometrics. *Anal Chem.* 2019;91(1):704–42.
41. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. *Mass Spectrom Rev.* 2007;26(1):51–78.
42. Kim HK, Choi YH, Verpoorte R. NMR-based metabolomic analysis of plants. *Nat Protoc.* 2010;5(3):536–49.
43. Bourgaud F, Gravot A, Milesi S, Gontier E. Production of plant secondary metabolites: a historical perspective. *Plant Sci.* 2001;161(5):839–51.